Results for 'CMO ADC'
Content Type: All
Sorted by: Relevance
Showing 11 to 20 results of 442
News
Piramal’s Healthcare Vertical Further Expand Commercial ADC Capacity
Piramal | Healthcare was the first contract supplier of ADCs globally.
News
VivaMab and ADC Therapeutics Announce Antibody Licensing Deal
Licensing deal for novel ADC candidate to target hematologic cancers.
News
Seattle Genetics and Oxford BioTherapeutics to Collaborate on ADCs for Cancer
Companies to combine proprietary technologies to generate novel ADC product candidates.
News
ADC Achieves ISO 9001 Certification
The most widely-recognized quality management certification has been awarded to ADC.
News
BioOutsource Expands ADC Characterization Capabilities
A global leader in ADC characterization, BioOutsource, partners with Glythera.
News
MedImmune Acquires Spirogen and Invests in ADC Therapeutics
MedImmune acquires 100% of Spirogen and enters into a collaboration agreement with ADC for two of their oncology programs.
News
VivaMab and ADC Therapeutics Announce Antibody Licensing Deal
VivaMab and ADC Therapeutics Sarl announced a licensing deal for a novel antibody against an undisclosed hematological cancer target.
News
Compugen Discloses Discovery of Five Potential Cancer Targets for ADC Therapy
ADC target discovery is company’s second focused discovery program utilizing its in silico predictive discovery infrastructure.
Poster
Homogeneous ADCs Bearing Two Different Payloads Show Strong Synergy In Tumor Killing
We presented a one-pot reaction to prepare site-specific ADCs using available mABs on hand without re-engineering. We have identified a novel non-cleavable linker, which increases not only ADC stability, but also potency. We also demonstrate synergy in cancer cell killing of hybrid ADC loaded with two different toxins
App Note / Case Study
ADC Therapeutics Drives Productivity with Labguru
Download this case study to learn more about how cloud-based lab management solution Labguru transformed ADC Therapeutics' research.
Advertisement
